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Abstract
Purpose Administration of chemotherapy in patients with
renal failure, treated with hemodialysis or continuous
ambulatory peritoneal dialysis (CAPD) is still a challenge
and literature data is scarce. Here we present a case study
of a patient on CAPD, treated with weekly and three-
weekly paclitaxel/carboplatin for recurrent ovarian cancer.
Experimental During the ﬁrst, second and ninth cycle of
treatment, blood, urine and CAPD samples were collected
for pharmacokinetic analysis of paclitaxel and total and
unbound carboplatin-derived platinum.
Results Treatment was well tolerated by the patient. No
excessive toxicity was observed and at the end of treatment
she was in a complete remission. The plasma pharmaco-
kinetics of paclitaxel were unaltered compared to historical
data, with neglectable urinary and CAPD clearance. In
contrast, the pharmacokinetics of carboplatin were altered,
with doubled half-lives compared to patients with normal
renal function. Of the administered carboplatin dose, up to
20% was cleared via the dialysate, while only up to 8% was
cleared via the urine.
Conclusion Paclitaxel and carboplatin can be safely
administered to patients with chronic renal failure on
CAPD. For paclitaxel the generally applied dose can be
administered, and although for carboplatin dose-adjustment
is required due to the diminished renal function, the dose
can be calculated using Calvert’s formula.
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Introduction
Platinum-based chemotherapy is commonly accepted as the
standard ﬁrst line treatment for ovarian cancer. Because of a
more favorable toxicity proﬁle, carboplatin is frequently
preferredover cisplatin[7,16,24,25,27,29].Carboplatin is
mainly cleared (70%) by renal excretion, with most of the
drug excreted unchanged in the urine over the ﬁrst 24 h in
patients with anormalrenalfunction(i.e.,GFR33–135 mL/
min) [15]. The renal clearance of carboplatin, in patients
with anormal renalfunction,isdependenton theglomerular
ﬁltrationrate(GFR).Calvert[3] showed inpharmacokinetic
studies that the renal clearance of carboplatin is linearly
related to the GFR and ever since than carboplatin doses are
commonly calculated by Calvert’s formula [3] (Eq. 1). In
the formula, the drug’s exposure, expressed as the area
under concentration time curve (AUC), is a set value,
depending on the chemotherapy schedule used.
Dose (mg) ¼ Target AUC ðmg/mL   minÞ
 ½ GFR (mL/min) þ 25 ð 1Þ
Calvert’s formula has been developed using data of
cancer patients with GFR from 33 to 135 mL/min, in
which the GFR is measured using the
51Cr-EDTA
clearance. However, due to the expensive and patient-
inconvenient use of the
51Cr-EDTA clearance, the GFR is
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Gault formula [5]. The substitution of the method for the
estimation of the GFR is questionable and results in less
predictive estimations of the carboplatin clearance [9] and
it is still unknown whether Calvert’s formula may also be
used for patients with GFR less than 10 mL/min and on
continuous ambulatory peritoneal dialysis (CAPD).
In ovarian cancer carboplatin is mostly combined with
paclitaxel in view of the proven added value of the latter
[29]. Paclitaxel is extensively metabolized by hepatic
cytochrome P450 enzymes and is mainly cleared by bil-
iary secretion, with less than 10% excreted by the kidneys
[21].
Studies describing the pharmacokinetics of carboplatin
and/or paclitaxel in patients with renal failure are scarce [1,
4, 6, 10, 17, 19, 21, 31, 32, 35–37]. As paclitaxel is pre-
dominantly cleared by hepatic metabolism and biliary
excretion, it was concluded that there is no need for dose
adjustment of paclitaxel in patients with renal failure [1,
19, 32, 37]. Furthermore, it was shown that Calvert’s for-
mula could be safely applied in patients with minimal renal
function (i.e., GFR values less than 10 mL/min) and on
hemodialysis, in which carboplatin is cleared via the dial-
ysate [4, 12, 35]. In patients on hemodialysis the GFR is set
at zero in Calvert’s formula (Eq. 1) to calculate the dose,
while the hemodialysis is started within 24 h after the start
of infusion [21].
Publications, supporting safe and efﬁcient therapies of
(cytotoxic) anticancer agents in patients on CAPD are even
more scarce [12, 20, 34]. To the best of our knowledge, to
date no reports have been published describing the phar-
macokinetics of paclitaxel in patients on CAPD, while the
pharmacokinetics of carboplatin have been described in a
single pediatric patient on CAPD [12], in which it was
concluded that carboplatin was not cleared by peritoneal
dialysis.
Here, we report on the pharmacokinetics of carboplatin
and paclitaxel in plasma, urine and peritoneal dialysate as
well as the clinical data of a patient with recurrent ovarian
cancer on CAPD.
Patient and methods
Patient
A 49-year-old Caucasian female was diagnosed with
ovarian cancer FIGO stage IIIc in 2002. The initial treat-
ment consisted of total abdominal hysterectomy and
bilateral salpingo-oophorectomy, omentectomy and resec-
tion of all macroscopic tumor lesions. Postoperatively
treatment consisted of nine cycles of three-weekly paclit-
axel and carboplatin. The patient had preexistent
moderate renal failure (creatinine 200 lmol/L), most
probably due to longstanding hypertension. At the end of
the treatment a clinical complete remission of the ovarian
cancer was observed. During follow-up her renal function
deteriorated progressively and in 2004 she developed
end-stage renal failure for which chronic ambulatory
peritoneal dialysis was started. In 2005 she presented
with increasing plasma concentrations of the tumor
marker CA 125 and a few months later she had clinical
progressive disease with liver, spleen and lung metastases
and also retroperitoneal and inguinal lymph nodes
metastases.
By that time she dialyzed four times a day, using 2 L
bags of dialysis ﬂuid, in a scheme of twice daily 1.36%
glucose, once 2.27% glucose, each remaining 4–6 h in the
peritoneal cavity. During the night she used 7.5% glucose
(extraneal), which remained the peritoneal cavity for at
least 6 h.
She was then treated with six-weekly cycles of dose-
dense induction chemotherapy consisting of paclitaxel
90 mg/m
2, administered over 1 h, followed by a 1 h infu-
sion of carboplatin targeted at AUC 4 [2, 33]. At start of
therapy, while the patient was continuously treated with
peritoneal dialysis, serum creatinine was 778 lmol/L.
Subsequently, according to the protocol, in which after
induction chemotherapy with dose-dense weekly paclit-
axel carboplatin treatment is changed into standard three-
weekly paclitaxel carboplatin, she received six cycles of
three-weekly paclitaxel 175 mg/m
2, administered over
3 h, followed by a 1 h infusion of carboplatin at AUC 5.
The dose of carboplatin was calculated using Calvert’s
formula (Eq. 1,[ 3]) in which the GFR was calculated
according to the Cockcroft Gault formula [5]. Pharma-
cokinetics were performed. Because of renal failure, she
was already treated with erythropoietin at a dose of
10,000 IU once a week.
Pharmacokinetic sampling
For paclitaxel and carboplatin plasma pharmacokinetic
analysis, blood samples were collected during the ﬁrst and
second one-weekly cycles and the third three-weekly cycle
(i.e. cycle 9) in the presence of lithium heparin as antico-
agulant. Samples for paclitaxel analysis were taken at the
following time points: before the intravenous infusion,
halfway the infusion (i.e., 30 min during the 1 h infusion
and 1 h 30 min during the 3 h infusion), at the end of
infusion and at 30 min, 1, 2, 4, 6 and 24 h after the end of
infusion. Within 15 min after collection, plasma was sep-
arated by centrifugation at 3,000g for 10 min, which was
stored at T\-70C until analysis. For carboplatin anal-
ysis, blood samples were collected at the following time
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123points: before the intravenous infusion, 30 min after the
start of infusion, at the end of the 1 h infusion and at 1, 2,
3, 4 and 21 h after the end of infusion. Within 15 min after
collection, plasma was separated by centrifugation at
3,000g for 10 min. Subsequently, 500-lL aliquots of the
plasma supernatant were mixed with 1.0-mL aliquots of
ice-cold (-20C) ethanol and stored at T\-20C for a
maximum of 24 h. Ethanolic supernatant was collected by
centrifugation of the samples at maximum speed in an
Eppendorf centrifuge (23,000g) for 5 min after which the
clear supernatant was subsequently stored at T\-70C
until analysis. The remaining plasma supernatant, for the
analysis of carboplatin-derived total platinum, was stored
at T\-70C until analysis.
Peritoneal dialysis samples were also collected in hep-
arinized containers and stored at T\-70C until analysis.
Samples were collected up to 24 h after the start of the
paclitaxel infusion. The time of dialysis as well as the time
in the peritoneal cavity and the weight of each dialysis bag
was accurately recorded.
Urine samples, 800–1,150 mL per day, were collected
during the same time-period in polypropylene containers,
from which aliquots were stored at T\-70C pending
analysis.
Carboplatin analysis
Plasma concentrations of unbound carboplatin-derived
platinum were determined according to a method as
described for cisplatin-derived platinum [22]. For
unbound platinum analysis, on the day of analysis ali-
quots of 1,000 lL of the ethanolic supernatant were
evaporated to dryness under nitrogen at T = 80C, and
the residue reconstituted in 200 lL diluent (i.e., water
containing 0.2% (v/v) Triton X-100 and 0.06% (w/v)
cesium chloride). A volume of 20 lL, in duplicate, was
injected onto the graphite furnace of a Perkin Elmer
Model 4110 ZL atomic absorption spectrophotometer
(Uberlingen, Germany). Platinum peak areas were mea-
sured at 265.9 nm. The lower limit of quantitation was
established at 0.0300 lg/mL unbound platinum in plasma.
For total platinum analysis, plasma aliquots were accu-
rately sixfold diluted in diluent from which subsequently
also aliquots of 20 lL were injected onto the graphite
furnace. The lower limit of quantitation for total carbo-
platin-derived platinum was established at 0.200 lg/mL in
plasma.
Urine samples were analyzed, after a ﬁvefold dilution in
blank plasma prior to processing, as for total carboplatin-
derived platinum as described above.
Aliquots of 25–100 lL of peritoneal dialysis samples
were evaporated to dryness at T = 80C under nitrogen.
The pellets were subsequently dissolved in 100 lL blank
plasma and further processed as described above for total
carboplatin-derived platinum.
Paclitaxel analysis
Paclitaxel was quantitated on newly developed and vali-
dated methods by liquid chromatography coupled to
tandem mass-spectrometric detection (LC–MS/MS), based
on a method recently concisely described for docetaxel
[11]. Brieﬂy, to 100 lL plasma aliquots, 200 lL 100 ng/
mL docetaxel (10 ng/mL for the sensitive method) in 100%
acetonitrile was added. Subsequently, an aliquot of 1 mL
n-butylchloride was added, where after the samples were
vigorously mixed for 10 min. Subsequently, 1 mL aliquots
of supernatant, obtained by centrifugation at 18,000g for
10 min, were evaporated under a stream of nitrogen at
T = 70C. The residues were dissolved in 150 lL aliquots
of acetonitrile/water/formic acid (40:60:0.1 v/v/v), from
which aliquots of 5 lL (or 50 lL for the sensitive assay)
were injected onto an Alltima HP C18 HL 3 lm column
(50 9 2.1 mm internal diameter, Alltech Applied Science,
Breda, the Netherlands). The mobile phase, acetonitrile and
water with 0.1% (v/v) formic acid, was delivered using a
linear gradient setting at a ﬂow rate of 0.2 mL/min with the
percentage of acetonitrile changing from 50 to 100% in
1 min. A MicroMass Quatro Micro triple-quadropole mass
spectrometer [Waters Chromatography B.V. (Etten-Leur,
The Netherlands) ] was used for detection in the positive
ion mode. The electrospray ionization was set at 3.8 kV
and at the cone voltage at 18 V. The collision energies
were set at 13 eV for paclitaxel and 18 eV for docetaxel,
with the collision gas (argon) pressure set at 0.004 mbar.
The dwell time per channel was set at 0.15 s.
Calibration curves were constructed in the range of 20–
1,000 ng/mL (2.00–100 ng/mL for the sensitive assay) by
plotting the peak area ratios of paclitaxel (854.3[286.2)
to the internal standard docetaxel (808.3[527.2) versus
the known paclitaxel concentration with a 1/concentration
weight factor. Urine samples were analyzed after dilution
in blank human lithium heparinized plasma prior to pro-
cessing, while peritoneal dialysis samples were processed
non-diluted.
Pharmacokinetic data analysis
Individual plasma pharmacokinetic parameters for both
total and unbound carboplatin-derived platinum as well as
for paclitaxel were estimated using noncompartmental
analysis using the software program WinNonLin 5.0
(Pharsight, CA, USA).
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Clinical
The patient tolerated the treatment well and without severe
side-effects or complications. The toxicity of the chemo-
therapy was limited to uncomplicated bone marrow
suppression (see Fig. 1).
No dose reductions of paclitaxel or carboplatin were
required during any cycles. Cycles 3 and 5 of the weekly
regimen and cycles 5 and 6 of the three-weekly regimen
were delayed with one week due to thrombocytopenia CTC
grade 2 and or leucocytopenia CTC grade 3. Despite use of
erythropoietin, which she already received prior to the start
of chemotherapy for her renal anemia, hemoglobin levels
decreased to a minimum of 4.2 mmol/L, because of which
red blood cell transfusions were given after the fourth and
sixth-weekly cycle and after the ﬁrst, third and ﬁfth three-
weekly cycle.
Except for alopecia CTC grade 2, no other non-hema-
tological toxicities were observed. The preexistent CTC
grade 1 neurotoxicity remained stable during treatment.
After the induction therapy with six-weekly paclitaxel/
carboplatin cycles a partial remission was achieved and at
the end of the three-weekly treatment the patient was in a
complete clinical remission. Serum CA 125 normalized
from 777 to 22 KU/L. After a progression free interval of
17 months the patient had a recurrence, which was once
more successfully retreated with weekly paclitaxel and
carboplatin.
Pharmacokinetics
In Table 1 a summary of the pharmacokinetic data of
carboplatin-derived total and unbound platinum as well as
of paclitaxel are presented, and in Fig. 2 the pharmacoki-
netic proﬁles of the compounds in plasma are shown. The
plasma pharmacokinetics of the 1- and 3-h infusion of
paclitaxel are comparable to those in patients with normal
renal function [13, 28, 30]. Paclitaxel was excreted only for
approximately 0.15% via the urine and 0.048% via the
peritoneal dialysate.
In contrast, the plasma pharmacokinetics of carboplatin-
derived platinum were different from historical data [8,
23]. Both unbound and total platinum showed slow clear-
ances of approximately 21 and 10 mL/min, respectively
and prolonged half-lives. During the ﬁrst 24 h after
administration, 14–20% of the administered dose of car-
boplatin was excreted in the peritoneal ﬂuid, with
peritoneal clearances in the range of 3.14–4.03 mL/min.
Carboplatin was excreted for only 6–8% via the kidneys,
with renal clearances in the range of 1.32–1.56 mL/min.
Discussion
This case study describes the pharmacokinetics of carbo-
platin and paclitaxel in an adult cancer patient with end-
stage renal failure, treated with CAPD. Studies as reported
here are of major importance for clinical oncology practice,
as (pharmacokinetic guided) clinical studies in patients on
substitution therapy for renal failure are scarce.
Paclitaxel, as shown in this report, can be safely
administered to patients on CAPD. The observed plasma
pharmacokinetics in the studied patient on CAPD were
comparable to those in patients with normal renal function
[13, 28, 30] and are in agreement with earlier reports of
patients with renal failure treated with paclitaxel [1, 18, 19,
Fig. 1 Absolute neutrophil (a), white blood cell (b) and platelet (c)
count during treatment. The solid lines represent the upper and lower
limits of normal values. The triangles indicate the treatment days in
the weekly schedule (open symbols) and the three-weekly (closed
symbols) schedule
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12326, 32, 35–37]. As paclitaxel is mainly cleared by biliary
secretion, following extensive metabolism by hepatic
cytochrome P450 enzymes, and also in patients with normal
renal function less than 10% is excreted by the kidneys [21],
dose-adjustments in patients with renal dysfunction are not
required. In addition, as shown earlier by Gelderblom et al.
[14], paclitaxel hardly distributes into the peritoneal cavity,
with \1.3% of systemic concentrations found in ascites,
which is in agreement with the neglectable clearance of
paclitaxel via peritoneal dialysis as reported here.
In contrast to paclitaxel, the pharmacokinetics of car-
boplatin-derived platinum in plasma were altered compared
to the pharmacokinetics in patients with normal renal
function [8, 23]. The half-lifves of total and unbound plat-
inum, as estimated during the ﬁrst 24 h, were almost
Table 1 Pharmacokinetic data of carboplatin-derived platinum and
paclitaxel
Parameter Course 1 Course 2 Course 9
Carboplatin-derived total platinum
Target AUC (mg min/mL) 4 4 5
Carboplatin dose (mg)
a 130 130 150
Platinum dose (mg) 68 68 79
Cmax (lg/mL) 4.84 4.98 5.12
AUC0-inf (lg h/mL) 106 119 137
CL (mL/min) 10.6 9.6 9.6
T½z (h) 17.6 19.6 19.3
Carboplatin-derived unbound platinum
Cmax (lg/mL) 3.93 3.66 4.67
AUC0-inf (lg h/mL) 51.6 54.2 67.7
AUC0-inf (mg min/mL)
b 5.89 6.19 7.73
CL (mL/min) 22.0 20.9 19.4
T½z (h) 10.5 11.7 10.4
Urine (%) 6.0 6.4 8.0
CLurine (mL/min)
c 1.32 1.34 1.56
Peritoneal dialysis (%) 14.3 19.3 20.1
CLperitoneal dialysis (mL/min)
c 3.14 4.03 3.37
Paclitaxel
Dose (mg/m
2) 9 09 01 7 5
Dose (mg) 140 140 270
Cmax (lg/mL) 3.71 2.43 3.26
AUC0-inf (lg h/mL) 6.39 6.07 11.7
CL (mL/min) 365 384 385
T½z (h) 9.1 9.9 7.8
Urine (%) 0.16 0.15 0.16
CLurine (mL/min)
d 0.57 0.59 0.60
Peritoneal dialysis (%) 0.047 0.048 0.049
CLperitoneal dialysis (mL/min)
d 0.17 0.18 0.47
a Dose calculated according to Eq. 1
b AUC of carboplatin (in stead of platinum) as expressed by Calvert
et al. [3]
c CL = total amount excreted in urine (or peritoneal dialysate)/AUC
unbound carboplatin-derived platinum in plasma
d CL = total amount excreted in urine (or peritoneal dialysate)/AUC
paclitaxel in plasma
Fig. 2 Plasma concentration time curves of carboplatin-derived
unbound (a) and total (b) platinum and of paclitaxel (c). Closed
symbols show the data of course nine of the studied patient. Open
symbols represent data (mean ± 2SD) of a reference population of
patients with normal renal function treated at our institute (n = 12 for
1 h carboplatin infusion dosed at AUC 5; n = 5 for 3 h paclitaxel
infusion dosed at 175 mg/m
2)
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123doubled with total and unbound platinum quantiﬁable up to
7 days after administration. Although the half-life of
unbound platinum was doubled, the estimated AUC of
unbound carboplatin in the three studied courses was no
more than 1.5 times the target AUC. The higher observed
AUCs of unbound carboplatin-derived platinum might be a
result of a slight overestimation of the GFR value. The GFR
value may be overestimated in patients on dialysis as the
observed plasma creatinine concentrations are determined
by the sum of the urinary and peritoneal dialysis clearances.
In contrast to glomerular ﬁltration the clearance via the
dialysis is purely gradient driven and depends on the
molecular weight of the compound. By setting the GFR
value at zero however, the contribution of the peritoneal
clearance and the (remaining) residual kidney function
would have been neglected and as a result the carboplatin
dose would have been underestimated. In addition, the slow
clearance and prolonged half-life of carboplatin did not lead
to dose limiting toxicities. Peritoneal dialysis cleared 14–
20% of the administereddose during the ﬁrst 24 h, while the
kidneys cleared 6–8% in the same time period. In patients
with a normal renal function or on hemodialysis, approxi-
mately 70% of the dose is cleared via the kidneys or
hemodialysate [6, 17, 21, 31]. The observed 20% clearance
of carboplatin via peritoneal dialysis in the studied patient is
high in contrast to an earlier study of English et al. [12]i n
which carboplatin was not cleared via peritoneal dialysis, as
stated by the authors. The discrepancy might be related to
the fact that in our study, a continuous peritoneal dialysis
was applied, while in the study of English et al. [12], the
peritoneal dialysis was only applied from 5 to 14 h after the
start of the carboplatin infusion. Moreover, in the study of
English et al. [12], still 30% of the administered carboplatin
dose was cleared via the kidneys, in contrast to only 6–8%
in our studied patient [12].
In conclusion, paclitaxel and carboplatin can be safely
administered to patients with chronic renal failure and on
CAPD. Paclitaxel can be administered at therapeutic doses
applied to patients with normal renal function. For carbo-
platin, dose-adjustments are required, however yet the
doses can be calculated using Calvert’s formula [3].
Open Access This article is distributed under the terms of the
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